Trial watch: Dendritic cell-based anticancer therapy

Figures & data

Table 1. Clinical trials recently initiated to test the therapeutic profile of dendritic cell-based interventions in cancer patients

Approach	Indications	Phase	Status	TAAs	Notes	Ref.
Autologous DCs	Follicular lymphoma	II	Recruiting	n.a.	Combined with RT and rituximab	NCT01926639
	Melanoma	I	Not yet recruiting	n.a.	Combined with adoptively transferred T cells plus IL-2	NCT01883297
DCs loaded with TAAs or peptides thereof	Breast carcinoma	I	Recruiting	ERBB2	As a single agent	NCT02061423
						NCT02063724
		I/II	Recruiting	ERBB2	As a single agent	NCT02061332
				CCNB1 WT1	Combined with anakinra and/or neoadjuvant chemotherapy	NCT02018458
	Glioblastoma multiforme	I	Recruiting	CD133	As a single agent	NCT02049489
	Hepatocellular carcinoma	I	Recruiting	Various	As a single agent	NCT01974661
	Lymphoma	II	Not yet recruiting	LMP2	Combined with a TLR9 agonist	NCT02115126
	Melanoma	I/II	Terminated	MLANA NY-ESO-1	As a single agent	NCT01944709
	Ovarian carcinoma	n.a.	Recruiting	FOLR1	As a single agent	NCT02111941
	Solid tumors	I	Not yet recruiting	NY-ESO-1	Combined with NY-ESO-1-targeting PBLs	NCT02070406
DCs loaded with tumor cell lysates	Brain neoplasms	I	Recruiting	Whole TAA set	Combined with temozolomide, RT and optional bevacizumab	NCT02010606
	Glioblastoma	n.a.	Available	Whole TAA set	As a single agent	NCT02146066
	Gliosarcoma	n.a.	Recruiting	Whole TAA set	Combined with temozolomide	NCT01957956
	Melanoma	II	Recruiting	Whole TAA set	Combined with RT and IFNα-based immunotherapy	NCT01973322
	Ovarian carcinoma	II	Not yet recruiting	Whole TAA set	Combined with GM-CSF	NCT02033616
			Recruiting	Whole TAA set	Combined with standard of care chemotherapy	NCT02107378
						NCT02107937
						NCT02107950
	Peritoneal malignancies	I/II	Not yet recruiting	Whole TAA set	Combined with celecoxib, IFNα and a TLR3 agonist	NCT02151448
	Prostate carcinoma	II	Active, not recruiting	Whole TAA set	Combined with docetaxel	NCT02105675
					Combined with hormone therapy	NCT02107391
					Combined with standard RT	NCT02107430
			Recruiting	Whole TAA set	Combined with radical primary prostatectomy	NCT02107404
					Combined with docetaxel	NCT02111577
					As a single agent	NCT02137746
	Sarcoma	I	Recruiting	Whole TAA set	Combined with imiquimod and gemcitabine	NCT01803152
Genetically modified DCs	Leukemia	I/II	Recruiting	n.a.	Combined with adoptively transferred CIK cells and DLIs	NCT01956630
	Melanoma	III	Not yet recruiting	Whole TAA set (bulk RNA)	As a single agent	NCT01983748
	Multiple myeloma	I	Recruiting	MAGEA3 MAGEC1 WT1	As a single agent after autologous HSCT	NCT01995708
	Renal cell carcinoma	n.a.	Not yet recruiting	n.a.	CD40LG-expressing DCs used as a neoadjuvant single agent	NCT02170389
		I/II	Active, not recruiting	MUC1 Survivin	Combined with adoptively transferred CIK cells	NCT01924156
In vivo targeting	Melanoma	II	Recruiting	NY-ESO-1	DEC-205-targeted variant of NY-ESO-1 combined with FLT3LG and polyICLC	NCT02129075
	Solid tumors	I	Recruiting	NY-ESO-1	DC-SIGN-targeting lentiviral vector encoding NY-ESO-1, used as single agent	NCT02122861
Mixed	Melanoma	I	Recruiting	NY-ESO-1 or whole TAA set	Combined with adoptively transferred T cells plus IL-2	NCT01946373
Sipuleucel-T	Prostate carcinoma	n.a.	Recruiting	PAP	As a single agent	NCT02042053
		I	Recruiting	PAP	As a single agent	NCT02036918
		II	Recruiting	PAP	Combined with enzalutamide	NCT01981122
			Not yet recruiting	PAP	Combined with tasquinimod	NCT02159950

Abbreviations: CCNB1, cyclin B1; CD40LG, CD40 ligand; CIK, cytokine-induced killer; DC, dendritic cell; DLI, donor lymphocyte infusion; ERBB2, v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2; FLT3LG, fms-related tyrosine kinase 3 ligand; FOLR1, folate receptor 1; GM-CSF, granulocyte macrophage colony-stimulating factor; HSCT, hematopoietic stem cell transplantation; IFNα, interferon α; IL-2, interleukin-2; LMP2, latent membrane protein 2; MAGEA3, melanoma antigen family A3; MAGEC1, melanoma antigen family C1; MLANA, melan A; MUC1, mucin 1; n.a., not applicable or not available; PAP, prostate acid phosphatase; PBL, peripheral blood lymphocyte; polyICLC, polyinosinic-polycytidylic acid stabilized in poly-L-lysine and carboxymethylcellulose; RT, radiation therapy; TAA, tumor-associated antigen; TLR9, Toll-like receptor 9; WT1, Wilms tumor 1. *Based on clinical trials initiated after August 2014, 1^st (source www.clinicaltrials.gov).